title: Differential activation of wild-type and variant forms of estrogen receptor alpha by synthetic and natural estrogenic compounds using a promoter containing three estrogen-responsive elements.
abstract: Structure-dependent estrogen receptor alpha (ER alpha) agonist and antagonist activities of synthetic and natural estrogenic compounds were investigated in human HepG2, MDA-MB-231 and U2 cancer cell lines. Compounds used in this study include 4'-hydroxytamoxifen, ICI 182,780, bisphenol-A (BPA), 2',4',6'-trichloro-4-biphenylol (3Cl-PCB-OH), 2',3',4',5'-tetrachloro-4-biphenylol (4Cl-PCB-OH), p-t-octylphenol, p-nonylphenol, naringenin, kepone, resveratrol, and 2,2-bis(p-hydroxyphenyl)-1,1,1-trichloroethane (HPTE). Cells were transfected with a construct (pERE(3)) containing three tandem estrogen responsive elements (EREs) and either wild-type estrogen receptor alpha (ER-wt) or variants expressing activation function-1 (ER-AF1) or AF-2 (ER-AF2). The ER agonist activities of the synthetic mono and dihydroxy aromatic compounds are comparable in all three-cell lines, whereas the activities of naringenin, kepone and resveratrol are dependent on cell context and expression of wild-type or variant forms of ER alpha. In contrast, the ER antagonist activities for these compounds were highly complex and, with the exception of 3Cl-PCB-OH, all compounds inhibited E2-induced wild-type or variant ER action. Results of this in vitro study suggest that the estrogenic and antiestrogenic activity of structurally diverse synthetic and natural estrogenic compounds is complex, and this is consistent with published data that often give contradictory results for these compounds.
authors.affiliation: Department of Veterinary Physiology and Pharmacology, Texas A and M University, 4466 TAMU, College Station, TX 77843-4466, USA.
authors.forename: K
authors.initials: K
authors.lastname: Yoon
authors.forename: L
authors.initials: L
authors.lastname: Pallaroni
authors.forename: M
authors.initials: M
authors.lastname: Stoner
authors.forename: K
authors.initials: K
authors.lastname: Gaido
authors.forename: S
authors.initials: S
authors.lastname: Safe
mesh_terms: D001559:Benzhydryl Compounds; D002455:Cell Division; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D047628:Estrogen Receptor alpha; D004967:Estrogens / Q000378:metabolism*; D004968:Estrogens, Non-Steroidal / Q000494:pharmacology; D000077267:Fulvestrant; D006801:Humans; D010636:Phenols / Q000494:pharmacology; D011078:Polychlorinated Biphenyls / Q000494:pharmacology; D011110:Polymorphism, Genetic; D011960:Receptors, Estrogen / Q000819:agonists / Q000235:genetics* / Q000378:metabolism*; D020218:Response Elements; D013629:Tamoxifen / Q000031:analogs & derivatives* / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured; D000098826:Bisphenol A Compounds
chemical_list: D001559:Benzhydryl Compounds; D004958:Estradiol; D004965:Estrogen Antagonists; D047628:Estrogen Receptor alpha; D004967:Estrogens; D004968:Estrogens, Non-Steroidal; D000077267:Fulvestrant; D010636:Phenols; D011078:Polychlorinated Biphenyls; D011960:Receptors, Estrogen; D013629:Tamoxifen; C104006:2',3',4',5'-tetrachloro-4-biphenylol; C105195:4-hydroxy-2',4',6'-trichlorobiphenyl; C016601:afimoxifene; C404910:2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane; C006780:bisphenol A; D000098826:Bisphenol A Compounds